U.S. FDA engagement report
@FDA - 592K followers on X
Measured over 29 original posts from a 30-day window, last computed on October 9, 2026.
Engagement
A typical post picks up 33 interactions against 592K followers, an engagement rate of 0.006%. Measured over 29 original posts, its engagement rate beats 26% of 20,444 tracked accounts of a similar size, which puts it in the middle of its size range rather than at either end. Posts are seen about 9.8K times each, and 0.336% of those impressions turn into an interaction. That is about 1.66% of the follower count, which is the gap between an audience on paper and an audience in a timeline. Posting runs at about 1.6 posts a day over the last 30 days, with activity on roughly 67% of days. Most posts go out around 14:00 UTC, and Wednesday is the busiest day of the week. Of the 29 posts sampled, 100% carry an image or video, 14% are part of a thread and 90% link out. The account's strongest tracked post pulled 619 interactions, about 19x its own typical post. Recurring topics include #childhoodcancermonth, #menopause, #testosterone.
Measured over 29 original posts from a 30-day window, last computed on October 9, 2026. Recurring tags: #childhoodcancermonth, #menopause, #testosterone.
Compared with accounts its own size
U.S. FDA's engagement rate beats 26% of the tracked X accounts closest to it in follower count (20,444 accounts, accounts of similar size (decile 10 of 10)). A percentile is spread evenly by construction, so 50 really is the middle of that group and 90 really is its top tenth.
On engagement per impression rather than per follower it beats 23% of the same group. When those two numbers disagree, the gap is about how far its posts travel rather than how people react to them.
Where this sits in the catalog
At 0.006%, U.S. FDA sits above the 10th percentile of the 205,374 accounts in this comparison. That places it in the bottom 25% band, which runs below 0.024%.
Show the percentile table
| Percentile | Engagement rate |
|---|---|
| 10th percentile | 0.004% |
| 25th percentile | 0.024% |
| 50th percentile | 0.143% |
| 75th percentile | 0.678% |
| 90th percentile | 2.55% |
| 99th percentile | 82.4% |
This ruler is the whole measured catalog, not a size-matched group: it shows where the raw rate falls across every account we can measure, all of which are large. For a like-for-like comparison, read the size-band percentile above instead. See how the bands are built
Posting timing
This account posts most often around 14:00 UTC, and Wednesday is its busiest day of the week. The bars below are the catalog-wide pattern, with this account's own busiest slot marked. They do not show how this account performs at each hour: we keep one aggregate per account, not one per hour, so that measurement does not exist in our data.
Show engagement by hour posted, utc as a table
| Hour (UTC) | Vs author median | Posts |
|---|---|---|
| 00:00 UTC | -1% | 89K |
| 01:00 UTC | -2% | 90K |
| 02:00 UTC | -3% | 88K |
| 03:00 UTC | -4% | 94K |
| 04:00 UTC | -5% | 76K |
| 05:00 UTC | -4% | 75K |
| 06:00 UTC | -5% | 86K |
| 07:00 UTC | -5% | 93K |
| 08:00 UTC | -4% | 108K |
| 09:00 UTC | -4% | 124K |
| 10:00 UTC | -3% | 129K |
| 11:00 UTC | -3% | 141K |
| 12:00 UTC | -3% | 154K |
| 13:00 UTC | -3% | 167K |
| 14:00 UTC | -4% | 173K |
| 15:00 UTC | -2% | 176K |
| 16:00 UTC | -3% | 171K |
| 17:00 UTC | -3% | 159K |
| 18:00 UTC | -2% | 149K |
| 19:00 UTC | -2% | 141K |
| 20:00 UTC | -1% | 131K |
| 21:00 UTC | 0% | 116K |
| 22:00 UTC | -2% | 100K |
| 23:00 UTC | -1% | 90K |
Show engagement by day of week as a table
| Day | Vs author median | Posts |
|---|---|---|
| Sunday | +5% | 393K |
| Monday | +1% | 483K |
| Tuesday | -2% | 520K |
| Wednesday | -3% | 472K |
| Thursday | -2% | 430K |
| Friday | -3% | 447K |
| Saturday | +2% | 393K |
Formats this account uses
Its own posting mix on the left, and what each of those formats does across every account we track on the right. Only formats where the effect clears our publish test appear here, so an empty row is a format we could not measure rather than one that does nothing.
| Format | This account | Catalog effect | 95% interval | Accounts behind it |
|---|---|---|---|---|
| Image or video | 100% of posts | +111% | +108% to +115% | 34K |
| Outbound link | 90% of posts | -41% | -42% to -40% | 32K |
| Typical length | - | +15% | +14% to +16% | 32K |
- 100% of this account's sampled posts carry an image or video. Across the catalog, posts with an image or video run 111% above the same accounts' other posts.
- 90% of its posts carry a link off X. Across the catalog, posts with an outbound link run 41% below the same accounts' other posts, so a large share of this account's output sits in the weakest bucket we measure.
- Its average post runs 326 characters, which falls in the over 280 characters band. Across the catalog, posts over 280 characters run 15% above the same accounts' other posts.
These are catalog-wide differences applied to this account's own posting mix, not a measurement of how each format performs for this account specifically. We keep one median per account, not one per format per account, so the second thing is not something this data can tell you.
Best tweets
- Jul 31, 202619x their median
We're getting a new name on X! Starting Aug. 7th, we become @FDA. If you follow us now, you don't have to change a thing to keep following us. New handle, same trusted public health information.
- Sep 11, 20267.2x their median
The @CDCgov has declared the Taylor Farms–related Cyclospora outbreak over. The FDA’s investigation and related activities remain ongoing. https://t.co/yNrlGuir7j See our new post-response page to learn more about the agency’s continued work and future efforts. https://t.co/Zsnv5IPMDJ
- Aug 27, 20266.2x their median
Great news from @GeneralMills – they've completed the removal of certified color from their entire U.S. cereal portfolio and are on track to remove them from all U.S. retail products by 2027! Who’s next? https://t.co/GL5Iq63vQO
- Aug 5, 20265.5x their median
What if getting a new therapy to patients could happen months faster? Right now, starting a clinical trial in the U.S. takes much longer than in other countries, which means patients sometimes have to travel overseas just to access investigational treatments. To address this, the FDA is piloting a new approach called the Expedited IND Program, which brings in specialized research institutions to work alongside drug developers earlier in the process. Think of it like adding an expert co-pilot to help navigate the path to clinical trials so issues get caught and resolved sooner, and promising therapies reach patients faster. Want to learn more or share your perspective? Join our free stakeholder webinar on Aug. 6 and check out our Request for Information. https://t.co/fi6WPcM40e
- Oct 1, 20265.4x their median
Today, we approved the first heart valve device designed to grow with children. The Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease can be expanded after surgery to keep pace with growth. The adjustable valve may mean fewer repeat surgeries for children as they get older. https://t.co/EakmrdVaxf Congenital heart defects are among the most common types of birth defects in the United States, affecting about 1 in every 100 births. The valve was approved through the premarket approval pathway, the FDA's most rigorous review process for medical devices.
- Sep 2, 20265.4x their median
Clinical trial data — wherever collected — must be reliable, inspectable, and ethically derived. If FDA can't inspect a site, that's a material factor in your regulatory strategy, not a footnote. Good clinical practice protects patients. The FDA will enforce it. https://t.co/Cpi7XMsEhC
- Aug 19, 20264.3x their median
Today, we approved a one-time gene therapy product for treatment as an adjunct to nutritional management of patients 8 years of age and older with glycogen storage disease type Ia (GSDIa). This is the first therapy approved for this condition in patients 8 and older. https://t.co/LekXwWvpj9
- Aug 6, 20264.3x their median
Today, FDA granted approval to a genetically modified oncolytic viral therapy for adults with resistant advanced melanoma. This approval underscores FDA’s commitment to using every available regulatory tool to help bring meaningful treatment options to patients with serious diseases. https://t.co/OrrDGp3iE9
- Jul 24, 20263.4x their median
Midwest Poultry Services, L.P. is recalling certain shell eggs due to potential Salmonella contamination. The recalled eggs were produced in Texas between June 6–July 3, 2026, with sell by/best by dates of July 20–Aug. 17. Check for carton codes P-1950 or 0840962 with Julian Dates 157–184. Consumers should check their refrigerators for recalled eggs and throw them away or return to place of purchase for a refund. https://t.co/o09GBP9cwQ
- Aug 20, 20263.2x their median
FDA just released a white paper on digitally derived measures (DDMs), explaining how wearables & #AI can capture real-time, real-life health outcomes that goes beyond the clinic visit. Digital health technologies (DHTs) are expanding what we understand about a participant's health, capturing data continuously, and in the context of everyday life. Learn more: https://t.co/YftRL4mQUl
Ranked by total interactions across everything we have tracked for this account, which is a longer history than the 30-day window the rates above use. The multiple compares each post to this account's own median.
Recurring topics
The most frequent hashtags in the sampled posts. They describe what this account writes about; they are not a performance signal, and the catalog-wide breakdown on the hub shows how little hashtag count moves.
Buy or sell Twitter (X) accounts - escrow-protected
PlayerSells is an escrow marketplace for Twitter (X) accounts. Every deal is protected, with no middleman risk.
Reading these numbers
A typical post picks up 33 interactions against 592K followers, an engagement rate of 0.006%. Measured over 29 original posts, its engagement rate beats 26% of 20,444 tracked accounts of a similar size, which puts it in the middle of its size range rather than at either end. Posts are seen about 9.8K times each, and 0.336% of those impressions turn into an interaction. That is about 1.66% of the follower count, which is the gap between an audience on paper and an audience in a timeline. Posting runs at about 1.6 posts a day over the last 30 days, with activity on roughly 67% of days. Most posts go out around 14:00 UTC, and Wednesday is the busiest day of the week. Of the 29 posts sampled, 100% carry an image or video, 14% are part of a thread and 90% link out. The account's strongest tracked post pulled 619 interactions, about 19x its own typical post. Recurring topics include #childhoodcancermonth, #menopause, #testosterone.
- What is U.S. FDA's engagement rate on X?
- U.S. FDA (@FDA) has an engagement rate of 0.006%, based on the median interactions across 29 original posts from the last 30 days against 592,422 followers. Replies, reposts and quote-posts of other people are excluded from that sample.
- Is that a good engagement rate?
- At 0.006%, U.S. FDA sits above the 10th percentile of the 205,374 accounts in this comparison. Those comparison accounts are all large ones, because our scanning cadence is weighted towards big accounts, so this is a ranking among peers of similar scale rather than a ranking across X.
- Does @FDA have real engagement?
- Its engagement rate beats 26% of the tracked X accounts closest to it in follower count (20,444 accounts), which puts it in the middle of its size range group. Ranking inside a size band matters because engagement rate falls as accounts grow, so a raw rate would mostly re-measure the follower count. It is a starting point for a look at follower quality, not a verdict on it.
- When does @FDA post?
- Most posts go out around 14:00 UTC, and Wednesday is its busiest day, at roughly 1.63 posts per day across the measured window.